Literature DB >> 15536030

Kinetics of compensatory gait in persons with myelomeningocele.

Elena M Gutierrez1, Asa Bartonek, Yvonne Haglund-Akerlind, Helena Saraste.   

Abstract

This study investigated the kinetic strategy and compensatory mechanisms during self-ambulatory gait in children with lumbo-sacral myelomeningocele. Thirty-one children with mid-lumbar to low-sacral myelomeningocele who walked without aids and 21 control children were evaluated by three-dimensional gait analysis. Joint moments in all planes at the hip and knee and sagittal moments at the ankle, as well as joint power and work done at all three joints, were analyzed. Joint moment capacity lost due to plantarflexor and dorsiflexor weakness was provided instead by orthotic support, but other joints were loaded more to compensate for the weakness at the ankles and restricted ankle motion. Subjects with total plantarflexor and dorsiflexor paresis and strength in the hip abductors had more knee extensor loading due to plantarflexor weakness and dorsiflexion angle of the orthotic ankle joint. The subjects with orthoses also generated more power at the hip to supplement the power generation lost to plantarflexor weakness and fixed ankles. The most determinant muscle whose paresis changes gait kinetics was the hip abductor. Hip abductor weakness resulted in a characteristic pattern where the hips displayed an eccentric adduction moment, mediating energy transfer into the lower limbs, and the hips replaced the knees as power absorbers in early stance. Joint moment, power and work analyses complement a kinematic analysis to provide a complete picture of how children who have muscle paresis recruit stronger muscle groups to compensate for weaker ones.

Entities:  

Mesh:

Year:  2005        PMID: 15536030     DOI: 10.1016/j.gaitpost.2003.11.002

Source DB:  PubMed          Journal:  Gait Posture        ISSN: 0966-6362            Impact factor:   2.840


  8 in total

1.  Upper extremity dynamics during Lofstrand crutch-assisted gait in children with myelomeningocele.

Authors:  Brooke A Slavens; Jamie Frantz; Peter F Sturm; Gerald F Harris
Journal:  J Spinal Cord Med       Date:  2007       Impact factor: 1.985

2.  Factors Associated with Mobility Outcomes in a National Spina Bifida Patient Registry.

Authors:  Brad E Dicianno; Amol Karmarkar; Amy Houtrow; Theresa M Crytzer; Katelyn M Cushanick; Andrew McCoy; Pamela Wilson; James Chinarian; Jacob Neufeld; Kathryn Smith; Diane M Collins
Journal:  Am J Phys Med Rehabil       Date:  2015-12       Impact factor: 2.159

3.  Limiting factors in peak oxygen uptake and the relationship with functional ambulation in ambulating children with spina bifida.

Authors:  J F De Groot; T Takken; M A G C Schoenmakers; L Vanhees; P J M Helders
Journal:  Eur J Appl Physiol       Date:  2008-07-10       Impact factor: 3.078

4.  Vestibular evoked myogenic potentials in children affected by myelomeningocele.

Authors:  Pasqualina M Picciotti; Antonella Fiorita; Lea Calò; Mariapina Battista; Valentina Paolucci; Emanuele Ausili; Luca Massimi; Claudia Rendeli
Journal:  Childs Nerv Syst       Date:  2012-05-05       Impact factor: 1.475

5.  [Functional impact of carbon fiber springs in ankle-foot orthoses].

Authors:  M Alimusaj; I Knie; S Wolf; A Fuchs; F Braatz; L Döderlein
Journal:  Orthopade       Date:  2007-08       Impact factor: 1.087

6.  Assessment of waveform similarity in clinical gait data: the linear fit method.

Authors:  M Iosa; A Cereatti; A Merlo; I Campanini; S Paolucci; A Cappozzo
Journal:  Biomed Res Int       Date:  2014-07-13       Impact factor: 3.411

Review 7.  Development and decline of upright gait stability.

Authors:  Marco Iosa; Augusto Fusco; Giovanni Morone; Stefano Paolucci
Journal:  Front Aging Neurosci       Date:  2014-02-05       Impact factor: 5.750

8.  Gait dynamics in the wide spectrum of children with arthrogryposis: a descriptive study.

Authors:  Marie Eriksson; Åsa Bartonek; Eva Pontén; Elena M Gutierrez-Farewik
Journal:  BMC Musculoskelet Disord       Date:  2015-12-09       Impact factor: 2.362

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.